Source: Danny Green
Overview of Rafael Holdings, Inc.
Rafael Holdings, Inc. (NYSE:RFL) is a reputable firm whose operations are centered on developing and commercializing novel cancer therapies. Through its subsidiaries, RFL has been able to maintain a keen focus on the research and development of oncology drugs, positioning it as a crucial player in the fight against cancer.
As part of the broader biotech industry, RFL competes within an environment that is teeming with other biotech firms. Some of its key competitors include Scholar Rock Holding Corporation, Evelo Biosciences, Inc., Verrica Pharmaceuticals Inc., and Replimune Group, Inc. These companies all share a common goal: to innovate and commercialize therapies that can improve the lives of patients battling various forms of cancer.
Evaluating RFL’s Financial Performance
In assessing the financial performance of any firm, one critical metric to consider is the Return on Invested Capital (ROIC). The ROIC essentially measures how efficiently a company is using its capital to generate profits. With RFL’s ROIC standing at -34.90%, it is significantly lower than its Weighted Average Cost of Capital (WACC) of 7.93%.
The WACC is the average rate of return a company is expected to pay its investors – the holders of its equity and debt. When a company’s ROIC is lower than its WACC, it indicates that the company is not generating returns above its cost of capital.
In RFL’s case, the ROIC to WACC ratio stands at -4.40, further confirming this situation. However, when compared to its peers, RFL’s capital utilization appears relatively more efficient.
Comparison with Peer Companies
Among its peers, Scholar Rock Holding Corporation (SRRK) has a ROIC of -101.98% and a WACC of 6.82%. These figures result in a ROIC to WACC ratio of -14.96. This ratio suggests that SRRK is less efficient in utilizing its capital compared to RFL.
Evelo Biosciences, Inc. (EVLO) is another peer with a ROIC of -199.73% and a WACC of 9.04%. The company’s ROIC to WACC ratio of -22.10 underscores its inefficiency in capital utilization, further emphasizing RFL’s relative efficiency.
Most Efficient Peer: Verrica Pharmaceuticals Inc.
Among all the peer companies, Verrica Pharmaceuticals Inc. (VRCA) emerges as the most efficient, with a ROIC to WACC ratio of -4.13. Even though all the companies under comparison have negative ratios, VRCA’s ratio is the least negative, indicating a better capital efficiency.
Lastly, Replimune Group, Inc. (REPL) also shows less favorable performance figures with a ROIC of -71.09% and a WACC of 7.47%. These figures result in a ROIC to WACC ratio of -9.52, indicating a less efficient use of capital.
Final Remarks
While all the companies analyzed are operating with negative ROIC to WACC ratios, highlighting the inherent challenges and risks in the biotech industry, some are faring better than others. Despite the negative figures, Rafael Holdings, Inc. is demonstrating a relatively efficient use of its capital, especially when compared to some of its peers.